Hypera S.A. (HYPMY) Stock

About Hypera S.A.

Hypera S.A. is a prominent pharmaceutical enterprise primarily operating within Brazil. The company maintains a diverse product portfolio that includes a vast array of prescription medications, marketed under numerous brand names such as Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid. Beyond prescription drugs, Hypera S.A. also provides dermo-cosmetic solutions, notably through its Mantecorp Skincare line. Its consumer health segment features well-known brands including Apracur, Benegrip, Coristina d, Engov, Epocler, and Estomazil, among others. Furthermore, the company offers nutritional and vitamin supplements, with labels such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. Hypera S.A. is also a producer and distributor of a range of similar and generic medicines, including its Neo Química brand, as well as products identified by active ingredients like Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel. Initially known as Hypermarcas S.A., the company officially rebranded to Hypera S.A. in February 2018. Its corporate headquarters are located in São Paulo, Brazil.

Hypera S.A. is headquartered in BR.

Hypera S.A. (HYPMY) stock trades at $4.00 with a market capitalization of $2.82B. The stock is valued at a price-to-earnings (P/E) ratio of 7.63, price-to-book of 0.91, price-to-sales of 1.65. Over the past 52 weeks the stock has ranged between $3.71 and $5.50, and currently trades 27.3% below its 52-week high. It pays a dividend yielding 5.00%.

On profitability, Hypera S.A. generates a return on equity (ROE) of 13.23%, above the typical market average, return on capital employed of 9.45%, an operating margin of 28.54%, a net profit margin of 19.48%.

Official website: www.hypera.com.br